
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try

Bristol Myers Squibb maintains a powerful portfolio in oncology and hematology while trading at a low valuation multiple. Novo Nordisk dominates the rapidly expanding markets for obesity and diabetes treatments with high net margins.

Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs.

When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.

Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look shaky but cash tells a different story?

Vanguard quietly runs an actively managed value fund that hunts for bargains across every company size, and it just beat its famous index sibling over the past year. Before you switch, check what it asks of you in return.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026.

MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.

Growth portfolio revenue rose 12% year over year to $7.7 billion. Eight growth portfolio medicines annualized over $1 billion each.